Bayer's Yaz May Face More Labeling Changes On Blood Clot Warnings

The combination oral contraceptive's warnings were updated in March, but two recently published epidemiological studies that found a higher risk of venous thromboembolic events with drospirenone compared to levonorgestrel could result in another labeling revision.